In VitroPubMed ID: 37142557·2023

Triple Agonist Therapy: Comparative Analysis of Glucagon Receptor Signaling Contributions

Bahler L, Barta Z, Scherer PE, et al.

Journal of Biological Chemistry, 2023

Key finding

Retatrutide showed 3.2-fold higher activation of thermogenic genes (UCP1, PGC1α) in brown adipocytes compared to tirzepatide, mediated by glucagon signaling.

Summary

Cell-based mechanistic studies comparing retatrutide, tirzepatide, and semaglutide effects on hepatic glucose production and thermogenic gene expression via glucagon signaling.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT